Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer
These findings suggest that the mechanical barrier of HA is the major reason responsible for the resistance developed during prolonged anti-angiogenesis in EGC. Incorporating PEGPH20 into the existing treatment regimen is promising to improve outcomes for patients with EGC.
Authors
- Maarten F. Bijlsma (ORCID: https://orcid.org/0000-0001-6627-3229)
- Sybren L. Meijer (ORCID: https://orcid.org/0000-0002-6953-2406)
- Hanneke W.M. van Laarhoven (ORCID: https://orcid.org/0000-0003-1274-5643)
- César Oyarce
- Dajia Liu
- Cynthia Waasdorp (ORCID: https://orcid.org/0009-0000-9162-7367)
- Lihui Guo (ORCID: https://orcid.org/0000-0002-8931-8378)
- Sanne Bootsma
Institutions
- Amsterdam Neuroscience (NL)
- Oncode Institute (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1016/j.biopha.2024.117261
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Eli Lilly and Company
- Halozyme